Cardinal Health, Inc. CAH

Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

Con 4 acciones de CAH (USD 928,12) habrías recibido USD 8,24 en dividendos en los últimos 12 meses.

• Zacks Investment Research 2 oct

  Zacks Industry Outlook Highlights McKesson, Cardinal Health, Becton, Dickinson, Merit Medical Systems and ProDex

  The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, and technology adoption, with the global market expected to reach $318.77 billion by 2031. However, tariffs, commodity inflation, and policy-driven pricing changes present headwinds. Five key stocks—McKesson, Cardinal Health, Becton Dickinson, Merit Medical Systems, and ProDex—are highlighted as well-positioned to capitalize on favorable industry trends through 2026.

  

• Zacks Investment Research 1 oct

  5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve

  The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, AI automation, and aging demographics. The global medical supplies market is expected to reach $318.77 billion by 2031 with a 10% CAGR. However, tariffs, commodity inflation, and pharmaceutical pricing changes remain headwinds. Key industry players show mixed near-term prospects with the industry trading at favorable valuations compared to broader markets.

  

• Zacks Investment Research 22 sept

  Cardinal Health (CAH) Stock Moves -1.64%: What You Should Know

  Cardinal Health (CAH) closed down 1.64% and is expected to report EPS of $2.92 (up 14.51% YoY) with revenue of $66.96 billion (up 4.6% YoY). The stock holds a Zacks Rank #3 (Hold) with a Forward P/E of 17.99, trading at a premium to its industry average. The Medical-Dental Supplies industry ranks in the top 44% of all industries.

  

• Zacks Investment Research 22 sept

  Cardinal (CAH) Is Considered a Good Investment by Brokers: Is That True?

  While Cardinal Health (CAH) has a strong average brokerage recommendation of 1.39 (Strong Buy equivalent) from 18 firms, the article cautions that broker recommendations are often overly optimistic due to vested interests. The Zacks Rank system rates CAH as a #3 (Hold), citing unchanged earnings estimates of $12.55 for the current year, suggesting the stock may perform in line with the broader market in the near term.

  

• The Motley Fool 18 sept

  AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

  AbbVie and Bristol Myers Squibb are compared as pharmaceutical investment options for 2026. AbbVie is recommended as the better buy due to its successful immunology franchise with Skyrizi and Rinvoq driving growth, diversification into aesthetics and neuroscience, and having navigated its patent cliff challenges. Bristol Myers Squibb, while cheaper on valuation metrics and maintaining strong profit margins, faces revenue stagnation, legal uncertainties from a Celgene acquisition lawsuit, and is still working through its own portfolio transition challenges.